Skip to main content
Equibles
IDXG logo

IDXG · Interpace Biosciences, Inc. · Metrics

Track IDXG — free

Use IDXG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IDXG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.25 At close · Feb 25
Rebalance outlook locked
Market Cap
$42.19M
Shares
5.54M
Volume · Feb 25 186.4K Avg daily vol (3M) —

IDXG metrics

41 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.25
Market cap
$42.19M

Price action

20 metrics
Price change (1W)
—
Price change (30D)
—
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
5.54M

Valuation

12 metrics
P / E (TTM)
0.6
Trailing earnings · reciprocal yield 155.4%
PEG ratio
0.0
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.2×
reciprocal yield 85.7%
P / book
1.8
reciprocal yield 55.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
9.5
reciprocal yield 10.6%
Earnings yield
57.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2021-01-20

Profitability

9 metrics
Gross margin
63.7%
Operating margin
11.5%
Trailing 12 months
Net margin
67.6%
Gross profit (TTM)
$23.04M
Operating profit (TTM)
$4.17M
Net income (TTM)
$24.45M
Trailing 12 months
Diluted EPS (TTM)
$5.05
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$25.25

Growth

11 metrics
Revenue growth YoY
-1.1%
Year over year
Net income growth YoY
+266.7%
Revenue (TTM)
$36.14M
Trailing 12 months
EPS growth YoY
+122.5%
Shares change YoY
+526.6%
Year over year · more shares
Revenue CAGR (3Y)
+89.6%
Revenue CAGR (5Y)
+3.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
105.2%
Return on assets
70.8%
Debt / equity
—
Current ratio
2.2
EBITDA (TTM)
$4.64M
Free cash flow (TTM)
—
Quick ratio
2.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.69M
Total assets
$34.55M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$4.46M
Capital expenditures (TTM)
$353,000
R&D (TTM)
$594,000
SG&A (TTM)
—
Stock compensation (TTM)
$19,000
R&D / revenue
1.6%
Stock compensation / revenue
0.1%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1054102 CUSIP 46062X303 Visit website Investor relations